Newsroom

Ivantis Announces 3 Year Results of Australian SPECTRUM Registry for Hydrus Microstent (November, 2019)
View

Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent (October, 2019)
View

Ivantis Announces Groundbreaking 3 Year Results from FDA Clinical Trial; First Device in Minimally Invasive Glaucoma Surgical (MIGS) Category to Demonstrate Significant Long Term Reduction of Severe Major Surgeries for Glaucoma Patients (May, 2019)
View

Ivantis Announces Publication of Landmark Comparative MIGS Clinical Trial Results in Leading Ophthalmic Journal (April, 2019)
View

Ivantis Announces 24-Month Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial (March, 2019)
View

Ivantis Announces FDA Approval for Its Innovative Hydrus® Microstent Device for Minimally Invasive Glaucoma Surgery (MIGS) (August, 2018)
View

New Data from the HORIZON Trial of the Hydrus® Microstent Shows Significantly Lower IOP and Medication Use at 24 Months in a US Patient Cohort (April, 2018)
View

lvantis Announces Results of Landmark Prospective, Randomized Comparative MIGS Clinical Trial (April, 2018)
View

lvantis FDA Clinical Trial of the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) Meets Endpoints, Exceeds Outcomes of Past MIGS Trials (November, 2017)
View

lvantis Completes Pre-Market Approval Submission for the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) (October, 2017)
View

lvantis Raises $25 Million Series C to Fund Future US Commercialization of the Hydrus® Microstent for Minimally Invasive Glaucoma Surgery (MIGS) (January, 2017)
View

Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent (October, 2019)
View

Please Select Your Country

Continue